Jump to content

Liposome

From Wikipedia, the free encyclopedia
Scheme of a liposome formed by phospholipids in an aqueous solution.
Liposomes are composite structures made of phospholipids and may contain small amounts of other molecules. Though liposomes can vary in size from low micrometer range to tens of micrometers, unilamellar liposomes, as pictured here, are typically in the lower size range with various targeting ligands attached to their surface allowing for their surface-attachment and accumulation in pathological areas for treatment of disease.[1]

A liposome is a small artificial vesicle, spherical in shape, having at least one lipid bilayer.[2] Due to their hydrophobicity and/or hydrophilicity, biocompatibility, particle size and many other properties,[2] liposomes can be used as drug delivery vehicles for administration of pharmaceutical drugs and nutrients,[3] such as lipid nanoparticles in mRNA vaccines, and DNA vaccines. Liposomes can be prepared by disrupting biological membranes (such as by sonication).

Liposomes are most often composed of phospholipids,[4] especially phosphatidylcholine, and cholesterol,[2] but may also include other lipids, such as those found in egg and phosphatidylethanolamine, as long as they are compatible with lipid bilayer structure.[5] A liposome design may employ surface ligands for attaching to desired cells or tissues.[1]

Based on vesicle structure, there are seven main categories for liposomes: multilamellar large (MLV), oligolamellar (OLV), small unilamellar (SUV), medium-sized unilamellar (MUV), large unilamellar (LUV), giant unilamellar (GUV) and multivesicular vesicles (MVV).[6] The major types of liposomes are the multilamellar vesicle (MLV, with several lamellar phase lipid bilayers), the small unilamellar liposome vesicle (SUV, with one lipid bilayer), the large unilamellar vesicle (LUV), and the cochleate vesicle. A less desirable form is multivesicular liposomes in which one vesicle contains one or more smaller vesicles.

Seven main categories for liposomes: multilamellar large (MLV), oligolamellar (OLV), small unilamellar (SUV), medium-sized unilamellar (MUV), large unilamellar (LUV), giant unilamellar (GUV) and multivesicular vesicles (MVV))[7].

Liposomes should not be confused with lysosomes, or with micelles and reverse micelles.[8] In contrast to liposomes, micelles typically contain a monolayer of fatty acids or surfactants.[9]

Discovery[edit]

The word liposome derives from two Greek words: lipo ("fat") and soma ("body"); it is so named because its composition is primarily of phospholipid.

Liposomes were first described by British hematologist Alec Douglas Bangham[10][11][12] in 1961 at the Babraham Institute, in Cambridge—findings that were published 1964. The discovery came about when Bangham and R. W. Horne were testing the institute's new electron microscope by adding negative stain to dry phospholipids. The resemblance to the plasmalemma was obvious, and the microscopic pictures provided the first evidence that the cell membrane is a bilayer lipid structure. The following year, Bangham, his colleague Malcolm Standish, and Gerald Weissmann, an American physician, established the integrity of this closed, bilayer structure and its ability to release its contents following detergent treatment (structure-linked latency).[13] During a Cambridge pub discussion with Bangham, Weissmann first named the structures "liposomes" after something which laboratory had been studying, the lysosome: a simple organelle whose structure-linked latency could be disrupted by detergents and streptolysins.[14] Liposomes are readily distinguishable from micelles and hexagonal lipid phases through negative staining transmission electron microscopy.[15]

Bangham, with colleagues Jeff Watkins and Standish, wrote the 1965 paper that effectively launched what would become the liposome "industry."Around that same time, Weissmann joined Bangham at the Babraham. Later, Weissmann, then an emeritus professor at New York University School of Medicine, recalled the two of them sitting in a Cambridge pub, reflecting on the role of lipid sheets in separating the cell interior from its exterior milieu. This insight, they felt, would be to cell function what the discovery of the double helix had been to genetics. As Bangham had been calling his lipid structures "multilamellar smectic mesophases," or sometimes "Banghasomes," Weissmann proposed the more user-friendly term liposome.[16][17]

Mechanism[edit]

A micrograph of phosphatidylcholine liposomes, which were stained with fluorochrome acridine orange. Method of fluorescence microscopy (1250-fold magnification).
Various types of phosphatidylcholine liposomes in suspension. Method of phase-contrast microscopy (1000-fold magnification). The following types of liposomes are visible: small monolamellar vesicles, large monolamellar vesicles, multilamellar vesicles, oligolamellar vesicles.

Encapsulation in liposomes[edit]

A liposome has an aqueous solution core surrounded by a hydrophobic membrane, in the form of a lipid bilayer; hydrophilic solutes dissolved in the core cannot readily pass through the bilayer. Hydrophobic chemicals associate with the bilayer. This property can be utilized to load liposomes with hydrophobic and/or hydrophilic molecules, a process known as encapsulation.[18] Typically, liposomes are prepared in a solution containing the compound to be trapped, which can either be an aqueous solution for encapsulating hydrophilic compounds like proteins,[19][20] or solutions in organic solvents mixed with lipids for encapsulating hydrophobic molecules. Encapsulation techniques can be categorized into two types: passive, which relies on the stochastic trapping of molecules during liposome formation, and active, which relies on the presence of charged lipids or transmembrane ion gradients.[18] A crucial parameter to consider is the "encapsulation efficiency," which is defined as the amount of compound present in the liposome solution divided by the total initial amount of compound used during the preparation.[21] In more recent developments, the application of liposomes in single-molecule experiments has introduced the concept of "single entity encapsulation efficiency." This term refers to the probability of a specific liposome containing the required number of copies of the compound.[22]

Delivery[edit]

To deliver the molecules to a site of action, the lipid bilayer can fuse with other bilayers such as the cell membrane, thus delivering the liposome contents; this is a complex and non-spontaneous event, however,[23] that does not apply to nutrients and drug delivery. By preparing liposomes in a solution of DNA or drugs (which would normally be unable to diffuse through the membrane) they can be (indiscriminately) delivered past the lipid bilayer.[24] Liposomes can also be designed to deliver drugs in other ways. Liposomes that contain low (or high) pH can be constructed such that dissolved aqueous drugs will be charged in solution (i.e., the pH is outside the drug's pI range). As the pH naturally neutralizes within the liposome (protons can pass through some membranes), the drug will also be neutralized, allowing it to freely pass through a membrane. These liposomes work to deliver drug by diffusion rather than by direct cell fusion. However, the efficacy of this pH regulated passage depends on the physiochemical nature of the drug in question (e.g. pKa and having a basic or acid nature), which is very low for many drugs.

A similar approach can be exploited in the biodetoxification of drugs by injecting empty liposomes with a transmembrane pH gradient. In this case the vesicles act as sinks to scavenge the drug in the blood circulation and prevent its toxic effect.[25] Another strategy for liposome drug delivery is to target endocytosis events. Liposomes can be made in a particular size range that makes them viable targets for natural macrophage phagocytosis. These liposomes may be digested while in the macrophage's phagosome, thus releasing its drug. Liposomes can also be decorated with opsonins and ligands to activate endocytosis in other cell types.

Regarding pH-sensitive liposomes, there are three mechanisms of drug delivery intracellularly, which occurs via endocytosis.[26] This is possible because of the acidic environment within endosomes.[26] The first mechanism is through the destabilization of the liposome within the endosome, triggering pore formation on the endosomal membrane and allowing diffusion of the liposome and its contents into the cytoplasm.[26] Another is the release of the encapsulated content within the endosome, eventually diffusing out into the cytoplasm through the endosomal membrane.[26] Lastly, the membrane of the liposome and the endosome fuse together, releasing the encapsulated contents onto the cytoplasm and avoiding degradation at the lysosomal level due to minimal contact time.[26]

Certain anticancer drugs such as doxorubicin (Doxil) and daunorubicin may be administered encapsulated in liposomes. Liposomal cisplatin has received orphan drug designation for pancreatic cancer from EMEA.[27] A study provides a promising preclinical demonstration of the effectiveness and ease of preparation of Valrubicin-loaded immunoliposomes (Val-ILs) as a novel nanoparticle technology. In the context of hematological cancers, Val-ILs have the potential to be used as a precise and effective therapy based on targeted vesicle-mediated cell death. [28]

The use of liposomes for transformation or transfection of DNA into a host cell is known as lipofection.

In addition to gene and drug delivery applications, liposomes can be used as carriers for the delivery of dyes to textiles,[29] pesticides to plants, enzymes and nutritional supplements to foods, and cosmetics to the skin.[30]

Liposomes are also used as outer shells of some microbubble contrast agents used in contrast-enhanced ultrasound.

Dietary and nutritional supplements[edit]

Until recently, the clinical uses of liposomes were for targeted drug delivery, but new applications for the oral delivery of certain dietary and nutritional supplements are in development.[31] This new application of liposomes is in part due to the low absorption and bioavailability rates of traditional oral dietary and nutritional tablets and capsules. The low oral bioavailability and absorption of many nutrients is clinically well documented.[32] Therefore, the natural encapsulation of lypophilic and hydrophilic nutrients within liposomes would be an effective method of bypassing the destructive elements of the gastric system and small intestines allowing the encapsulated nutrient to be efficiently delivered to the cells and tissues.[33]

The term nutraceutical combines the words nutrient and pharmaceutical, originally coined by Stephen DeFelice, who defined nutraceuticals as “food or part of a food that provides medical or health benefits, including the prevention and/or treatment of a disease”.[34] However, currently, there is no conclusive definition of nutraceuticals yet, to distinguish them from other food‐derived categories, such as food (dietary) supplements, herbal products, pre‐ and probiotics, functional foods, and fortified foods.[35] Generally, this term is used to describe any product derived from food sources which is expected to provide health benefits additionally to the nutritional value of daily food. A wide range of nutrients or other substances with nutritional or physiological effects (EU Directive 2002/46/EC) might be present in these products, including vitamins, minerals, amino acids, essential fatty acids, fibres and various plants and herbal extracts. Liposomal nutraceuticals contain bioactive compounds with health-promoting effects. The encapsulation of bioactive compounds in liposomes is attractive as liposomes have been shown to be able to overcome serious hurdles bioactives would otherwise encounter in the gastrointestinal (GI) tract upon oral intake.[36]

It is important to note that certain factors have far-reaching effects on the percentage of liposome that are yielded in manufacturing, as well as the actual amount of realized liposome entrapment and the actual quality and long-term stability of the liposomes themselves.[37] They are the following: (1) The actual manufacturing method and preparation of the liposomes themselves; (2) The constitution, quality, and type of raw phospholipid used in the formulation and manufacturing of the liposomes; (3) The ability to create homogeneous liposome particle sizes that are stable and hold their encapsulated payload. These are the primary elements in developing effective liposome carriers for use in dietary and nutritional supplements.

Manufacturing[edit]

The choice of liposome preparation method depends, i.a., on the following parameters:[38][39]

  1. the physicochemical characteristics of the material to be entrapped and those of the liposomal ingredients;
  2. the nature of the medium in which the lipid vesicles are dispersed
  3. the effective concentration of the entrapped substance and its potential toxicity;
  4. additional processes involved during application/delivery of the vesicles;
  5. optimum size, polydispersity and shelf-life of the vesicles for the intended application; and,
  6. batch-to-batch reproducibility and possibility of large-scale production of safe and efficient liposomal products

Useful liposomes rarely form spontaneously. They typically form after supplying enough energy to a dispersion of (phospho)lipids in a polar solvent, such as water, to break down multilamellar aggregates into oligo- or unilamellar bilayer vesicles.[5][24]

Liposomes can hence be created by sonicating a dispersion of amphipatic lipids, such as phospholipids, in water.[8] Low shear rates create multilamellar liposomes. The original aggregates, which have many layers like an onion, thereby form progressively smaller and finally unilamellar liposomes (which are often unstable, owing to their small size and the sonication-created defects). Sonication is generally considered a "gross" method of preparation as it can damage the structure of the drug to be encapsulated. Newer methods such as extrusion, micromixing[40][41][42] and Mozafari method[43] are employed to produce materials for human use. Using lipids other than phosphatidylcholine can greatly facilitate liposome preparation.[5]

Prospect[edit]

Pictorial representation of targeted theranostics liposomal delivery

Further advances in liposome research have been able to allow liposomes to avoid detection by the body's immune system, specifically, the cells of reticuloendothelial system (RES). These liposomes are known as "stealth liposomes". They were first proposed by G. Cevc and G. Blume[44] and, independently and soon thereafter, the groups of L. Huang and Vladimir Torchilin[45] and are constructed with PEG (Polyethylene Glycol) studding the outside of the membrane. The PEG coating, which is inert in the body, allows for longer circulatory life for the drug delivery mechanism. Studies have also shown that PEGylated liposomes elicit anti-IgM antibodies, thus leading to an enhanced blood clearance of the liposomes upon re-injection, depending on lipid dose and time interval between injections.[46][47] In addition to a PEG coating, some stealth liposomes also have some sort of biological species attached as a ligand to the liposome, to enable binding via a specific expression on the targeted drug delivery site. These targeting ligands could be monoclonal antibodies (making an immunoliposome), vitamins, or specific antigens, but must be accessible.[48] Targeted liposomes can target certain cell type in the body and deliver drugs that would otherwise be systemically delivered. Naturally toxic drugs can be much less systemically toxic if delivered only to diseased tissues. Polymersomes, morphologically related to liposomes, can also be used this way. Also morphologically related to liposomes are highly deformable vesicles, designed for non-invasive transdermal material delivery, known as transfersomes.[49]

Liposomes are used as models for artificial cells.

Liposomes can be used on their own or in combination with traditional antibiotics as neutralizing agents of bacterial toxins. Many bacterial toxins evolved to target specific lipids of the host cells membrane and can be baited and neutralized by liposomes containing those specific lipid targets.[50]

A study published in May 2018 also explored the potential use of liposomes as "nano-carriers" of fertilizing nutrients to treat malnourished or sickly plants. Results showed that these synthetic particles "soak into plant leaves more easily than naked nutrients", further validating the utilization of nanotechnology to increase crop yields.[51][52]

Machine learning has started to contribute to liposome research. For example, deep learning was used to monitor a multistep bioassay containing sucrose-loaded and nucleotides-loaded liposomes interacting with a lipid membrane-perforating peptide.[53] Artificial neural networks were also used to optimize formulation parameters of leuprolide acetate loaded liposomes[54] and to predict the particle size and the polydispersity index of liposomes.[55]

See also[edit]

References[edit]

  1. ^ Jump up to: a b Torchilin, V (2006). "Multifunctional nanocarriers". Advanced Drug Delivery Reviews. 58 (14): 1532–55. doi:10.1016/j.addr.2006.09.009. PMID 17092599. S2CID 9464592.
  2. ^ Jump up to: a b c Akbarzadeh, A.; Rezaei-Sadabady, R.; Davaran, S.; Joo, S. W.; Zarghami, N.; Hanifehpour, Y.; Samiei, M.; Kouhi, M.; Nejati-Koshki, K. (22 February 2013). "Liposome: classification, preparation, and applications". Nanoscale Research Letters. 8 (1): 102. Bibcode:2013NRL.....8..102A. doi:10.1186/1556-276X-8-102. ISSN 1931-7573. PMC 3599573. PMID 23432972.
  3. ^ "Cell Membranes - Kimball's Biology Pages". 16 August 2002. Archived from the original on 25 January 2009.
  4. ^ Mashaghi S., et al. Lipid Nanotechnology. Int J Mol Sci. 2013 Feb; 14(2): 4242–4282.
  5. ^ Jump up to: a b c Cevc, G (1993). "Rational design of new product candidates: the next generation of highly deformable bilayer vesicles for noninvasive, targeted therapy". Journal of Controlled Release. 160 (2): 135–146. doi:10.1016/j.jconrel.2012.01.005. PMID 22266051.
  6. ^ Moghassemi, Saeid; Dadashzadeh, Arezoo; Azevedo, Ricardo Bentes; Feron, Olivier; Amorim, Christiani A. (November 2021). "Photodynamic cancer therapy using liposomes as an advanced vesicular photosensitizer delivery system". Journal of Controlled Release. 339: 75–90. doi:10.1016/j.jconrel.2021.09.024. PMID 34562540. S2CID 237636495.
  7. ^ Moghassemi, Saeid; Dadashzadeh, Arezoo; Azevedo, Ricardo Bentes; Feron, Olivier; Amorim, Christiani A. (November 2021). "Photodynamic cancer therapy using liposomes as an advanced vesicular photosensitizer delivery system". Journal of Controlled Release. 339: 75–90. doi:10.1016/j.jconrel.2021.09.024. PMID 34562540. S2CID 237636495.
  8. ^ Jump up to: a b Stryer S. (1981) Biochemistry, 213
  9. ^ Mashaghi S., et al. Lipid Nanotechnology. Int J Mol Sci. 2013 Feb; 14(2): 4242–4282.
  10. ^ Bangham, A. D.; Horne, R. W. (1964). "Negative Staining of Phospholipids and Their Structural Modification by Surface-Active Agents As Observed in the Electron Microscope". Journal of Molecular Biology. 8 (5): 660–668. doi:10.1016/S0022-2836(64)80115-7. PMID 14187392.
  11. ^ Horne, R. W.; Bangham, A. D.; Whittaker, V. P. (1963). "Negatively Stained Lipoprotein Membranes". Nature. 200 (4913): 1340. Bibcode:1963Natur.200.1340H. doi:10.1038/2001340a0. PMID 14098499. S2CID 4153775.
  12. ^ Bangham, A. D.; Horne, R. W.; Glauert, A. M.; Dingle, J. T.; Lucy, J. A. (1962). "Action of saponin on biological cell membranes". Nature. 196 (4858): 952–955. Bibcode:1962Natur.196..952B. doi:10.1038/196952a0. PMID 13966357. S2CID 4181517.
  13. ^ Bangham A.D.; Standish M.M.; Weissmann G. (1965). "The action of steroids and streptolysin S on the permeability of phospholipid structures to cations". J. Molecular Biol. 13 (1): 253–259. doi:10.1016/s0022-2836(65)80094-8. PMID 5859040.
  14. ^ Sessa G.; Weissmann G. (1970). "Incorporation of lysozyme into liposomes: A model for structure-linked latency". J. Biol. Chem. 245 (13): 3295–3301. doi:10.1016/S0021-9258(18)62994-1. PMID 5459633.
  15. ^ YashRoy R.C. (1990). "Lamellar dispersion and phase separation of chloroplast membrane lipids by negative staining electron microscopy" (PDF). Journal of Biosciences. 15 (2): 93–98. doi:10.1007/bf02703373. S2CID 39712301.
  16. ^ Weissmann G.; Sessa G.; Standish M.; Bangham A. D. (1965). "ABSTRACTS". J. Clin. Invest. 44 (6): 1109–1116. doi:10.1172/jci105203. PMC 539946.
  17. ^ Geoff Watts (2010-06-12). "Alec Douglas Bangham". The Lancet. 375 (9731): 2070. doi:10.1016/S0140-6736(10)60950-6. S2CID 54382511. Retrieved 2014-10-01.
  18. ^ Jump up to: a b Mayer, Lawrence D.; Bally, Marcel B.; Hope, Michael J.; Cullis, Pieter R. (1 June 1986). "Techniques for encapsulating bioactive agents into liposomes". Chemistry and Physics of Lipids. 40 (2): 333–345. doi:10.1016/0009-3084(86)90077-0. ISSN 0009-3084. PMID 3742676.
  19. ^ Chaize, Barnabé; Colletier, Jacques-Philippe; Winterhalter, Mathias; Fournier, Didier (January 2004). "Encapsulation of Enzymes in Liposomes: High Encapsulation Efficiency and Control of Substrate Permeability". Artificial Cells, Blood Substitutes, and Biotechnology. 32 (1): 67–75. doi:10.1081/BIO-120028669. ISSN 1073-1199. PMID 15027802. S2CID 21897676.
  20. ^ Colletier, Jacques-Philippe; Chaize, Barnabé; Winterhalter, Mathias; Fournier, Didier (10 May 2002). "Protein encapsulation in liposomes: efficiency depends on interactions between protein and phospholipid bilayer". BMC Biotechnology. 2 (1): 9. doi:10.1186/1472-6750-2-9. ISSN 1472-6750. PMC 113741. PMID 12003642.
  21. ^ Edwards, Katie A.; Baeumner, Antje J. (28 February 2006). "Analysis of liposomes". Talanta. 68 (5): 1432–1441. doi:10.1016/j.talanta.2005.08.031. ISSN 0039-9140. PMID 18970482.
  22. ^ Longatte, Guillaume; Lisi, Fabio; Chen, Xueqian; Walsh, James; Wang, Wenqian; Ariotti, Nicholas; Boecking, Till; Gaus, Katharina; Gooding, J. Justin (23 November 2022). "Statistical predictions on the encapsulation of single molecule binding pairs into sized-dispersed nanocontainers". Physical Chemistry Chemical Physics. 24 (45): 28029–28039. Bibcode:2022PCCP...2428029L. doi:10.1039/D2CP03627D. ISSN 1463-9084. PMID 36373851.
  23. ^ Cevc, G; Richardsen, H (1993). "Lipid vesicles and membrane fusion". Advanced Drug Delivery Reviews. 38 (3): 207–232. doi:10.1016/s0169-409x(99)00030-7. PMID 10837758.
  24. ^ Jump up to: a b Barenholz, Y; G, Cevc (2000). Physical chemistry of biological surfaces, Chapter 7: Structure and properties of membranes. New York: Marcel Dekker. pp. 171–241.
  25. ^ Bertrand, Nicolas; Bouvet, CéLine; Moreau, Pierre; Leroux, Jean-Christophe (2010). "Transmembrane pH-Gradient Liposomes to Treat Cardiovascular Drug Intoxication". ACS Nano. 4 (12): 7552–8. doi:10.1021/nn101924a. PMID 21067150.
  26. ^ Jump up to: a b c d e Paliwal, Shivani Rai; Paliwal, Rishi; Vyas, Suresh P. (2015-04-03). "A review of mechanistic insight and application of pH-sensitive liposomes in drug delivery". Drug Delivery. 22 (3): 231–242. doi:10.3109/10717544.2014.882469. ISSN 1071-7544.
  27. ^ Anonymous (2018-09-17). "EU/3/07/451". European Medicines Agency. Retrieved 2020-01-10.
  28. ^ Georgievski A, Bellaye PS, Tournier B, Choubley H, Pais de Barros JP, Herbst M, Béduneau A, Callier P, Collin B, Végran F, Ballerini P, Garrido C, Quéré R (May 2024). "Valrubicin-loaded immunoliposomes for specific vesicle-mediated cell death in the treatment of hematological cancers". Cell Death Dis (15(5):328). doi:10.1038/s41419-024-06715-5. PMC 11088660. PMID 38734740.
  29. ^ Barani, H; Montazer, M (2008). "A review on applications of liposomes in textile processing". Journal of Liposome Research. 18 (3): 249–62. doi:10.1080/08982100802354665. PMID 18770074. S2CID 137500401.
  30. ^ Meure, LA; Knott, R; Foster, NR; Dehghani, F (2009). "The depressurization of an expanded solution into aqueous media for the bulk production of liposomes". Langmuir: The ACS Journal of Surfaces and Colloids. 25 (1): 326–37. doi:10.1021/la802511a. PMID 19072018.
  31. ^ Yoko Shojia; Hideki Nakashima (2004). "Nutraceutics and Delivery Systems". Journal of Drug Targeting.
  32. ^ Williamson, G; Manach, C (2005). "Bioavailability and bioefficacy of polyphenols in humans. II. Review of 93 intervention studies". The American Journal of Clinical Nutrition. 81 (1 Suppl): 243S–255S. doi:10.1093/ajcn/81.1.243S. PMID 15640487.
  33. ^ Bender, David A. (2003). Nutritional Biochemistry of Vitamins. Cambridge, U.K.: Cambridge University Press. OCLC 57204737.
  34. ^ DeFelice, Stephen L. (February 1995). "The nutraceutical revolution: its impact on food industry R&D". Trends in Food Science & Technology. 6 (2): 59–61. doi:10.1016/s0924-2244(00)88944-x. ISSN 0924-2244.
  35. ^ Santini, Antonello; Cammarata, Silvia Miriam; Capone, Giacomo; Ianaro, Angela; Tenore, Gian Carlo; Pani, Luca; Novellino, Ettore (2018-02-14). "Nutraceuticals: opening the debate for a regulatory framework". British Journal of Clinical Pharmacology. 84 (4): 659–672. doi:10.1111/bcp.13496. ISSN 0306-5251. PMC 5867125. PMID 29433155.
  36. ^ Porter, Christopher J. H.; Trevaskis, Natalie L.; Charman, William N. (March 2007). "Lipids and lipid-based formulations: optimizing the oral delivery of lipophilic drugs". Nature Reviews Drug Discovery. 6 (3): 231–248. doi:10.1038/nrd2197. ISSN 1474-1776. PMID 17330072. S2CID 29805601.
  37. ^ Szoka Jr, F; Papahadjopoulos, D (1980). "Comparative properties and methods of preparation of lipid vesicles (liposomes)". Annual Review of Biophysics and Bioengineering. 9: 467–508. doi:10.1146/annurev.bb.09.060180.002343. PMID 6994593.
  38. ^ Gomezhens, A; Fernandezromero, J (2006). "Analytical methods for the control of liposomal delivery systems". TrAC Trends in Analytical Chemistry. 25 (2): 167–178. doi:10.1016/j.trac.2005.07.006.
  39. ^ Mozafari, MR; Johnson, C; Hatziantoniou, S; Demetzos, C (2008). "Nanoliposomes and their applications in food nanotechnology". Journal of Liposome Research. 18 (4): 309–27. doi:10.1080/08982100802465941. PMID 18951288. S2CID 98836972.
  40. ^ Jahn, Andreas; Stavis, Samuel M.; Hong, Jennifer S.; Vreeland, Wyatt N.; DeVoe, Don L.; Gaitan, Michael (2010-04-27). "Microfluidic Mixing and the Formation of Nanoscale Lipid Vesicles". ACS Nano. 4 (4): 2077–2087. doi:10.1021/nn901676x. ISSN 1936-0851. PMID 20356060.
  41. ^ Zhigaltsev, Igor V.; Belliveau, Nathan; Hafez, Ismail; Leung, Alex K. K.; Huft, Jens; Hansen, Carl; Cullis, Pieter R. (2012-02-21). "Bottom-Up Design and Synthesis of Limit Size Lipid Nanoparticle Systems with Aqueous and Triglyceride Cores Using Millisecond Microfluidic Mixing". Langmuir. 28 (7): 3633–3640. doi:10.1021/la204833h. ISSN 0743-7463. PMID 22268499.
  42. ^ López, Rubén R.; Ocampo, Ixchel; Sánchez, Luz-María; Alazzam, Anas; Bergeron, Karl-F.; Camacho-León, Sergio; Mounier, Catherine; Stiharu, Ion; Nerguizian, Vahé (2020-02-25). "Surface Response Based Modeling of Liposome Characteristics in a Periodic Disturbance Mixer". Micromachines. 11 (3): 235. doi:10.3390/mi11030235. ISSN 2072-666X. PMC 7143066. PMID 32106424.
  43. ^ Colas, JC; Shi, W; Rao, VS; Omri, A; Mozafari, MR; Singh, H (2007). "Microscopical investigations of nisin-loaded nanoliposomes prepared by Mozafari method and their bacterial targeting". Micron. 38 (8): 841–7. doi:10.1016/j.micron.2007.06.013. PMID 17689087.
  44. ^ Blume, G; Cevc, G (1990). "Liposomes for the sustained drug release in vivo". Biochimica et Biophysica Acta (BBA) - Biomembranes. 1029 (1): 92–97. doi:10.1016/0005-2736(90)90440-y. PMID 2223816.
  45. ^ Klibanov, AL; Maruyama, K; Torchilin, VP; Huang, L (1990). "Amphipathic polyethyleneglycols effectively prolong the circulation time of liposomes". FEBS Letters. 268 (1): 235–237. doi:10.1016/0014-5793(90)81016-h. PMID 2384160. S2CID 11437990.
  46. ^ Wang, XinYu; Ishida, Tatsuhiro; Kiwada, Hiroshi (2007-06-01). "Anti-PEG IgM elicited by injection of liposomes is involved in the enhanced blood clearance of a subsequent dose of PEGylated liposomes". Journal of Controlled Release. 119 (2): 236–244. doi:10.1016/j.jconrel.2007.02.010. ISSN 0168-3659. PMID 17399838.
  47. ^ Dams, E.T.M.; Laverman, P.; Oyen, W.J.G.; Storm, G.; Scherphof, G.L.; Meer, J.W.M.; van der Corstens, F.H.M.; Boerman, O.C. (March 2000). "Accelerated blood clearance and altered biodistribution of repeated injections of sterically stabilized liposomes". The Journal of Pharmacology and Experimental Therapeutics. 292 (3). Amer soc pharmacology experimental therapeutics: 1071–9. PMID 10688625.
  48. ^ Blume, G; Cevc, G; Crommelin, M D A J; Bakker-Woudenberg, I A J M; Kluft, C; Storm, G (1993). "Specific targeting with poly (ethylene glycol)-modified liposomes: coupling of homing devices to the ends of the polymeric chains combines effective target binding with long circulation times". Biochimica et Biophysica Acta (BBA) - Biomembranes. 1149 (1): 180–184. doi:10.1016/0005-2736(93)90039-3. PMID 8318529.
  49. ^ Cevc, G (2004). "Lipid vesicles and other colloids as drug carriers on the skin". Advanced Drug Delivery Reviews. 56 (5): 675–711. doi:10.1016/j.addr.2003.10.028. PMID 15019752.
  50. ^ Besançon, Hervé; Babiychuk, Viktoriia; Larpin, Yu; Köffel, René; Schittny, Dominik; Brockhus, Lara; Hathaway, Lucy J.; Sendi, Parham; Draeger, Annette; Babiychuk, Eduard (14 February 2021). "Tailored liposomal nanotraps for the treatment of Streptococcal infections". Journal of Nanobiotechnology. 19 (1): 46. doi:10.1186/s12951-021-00775-x. PMC 7885208. PMID 33588835..
  51. ^ Karny, Avishai; Zinger, Assaf; Kajal, Ashima; Shainsky-Roitman, Janna; Schroeder, Avi (2018-05-17). "Therapeutic nanoparticles penetrate leaves and deliver nutrients to agricultural crops". Scientific Reports. 8 (1): 7589. Bibcode:2018NatSR...8.7589K. doi:10.1038/s41598-018-25197-y. ISSN 2045-2322. PMC 5958142. PMID 29773873.
  52. ^ Temming, Maria (2018-05-17). "Nanoparticles could help rescue malnourished crops". Science News. Retrieved 2018-05-18.
  53. ^ John-Herpin, Aurelian; Kavungal, Deepthy; von Mücke, Lea; Altug, Hatice (2020). "Infrared Metasurface Augmented by Deep Learning for Monitoring Dynamics between All Major Classes of Biomolecules". Advanced Materials. 33 (14): e2006054. doi:10.1002/adma.202006054. PMID 33615570.
  54. ^ Arulsudar, N.; Subramanian, N.; Murthy, R. S. R. (2005). "Comparison of artificial neural network and multiple linear regression in the optimization of formulation parameters of leuprolide acetate loaded liposomes". J Pharm Pharm Sci. 8 (2): 243–258. PMID 16124936.
  55. ^ Sansare, Sameera; Duran, Tibo; Mohammadiarani, Hossein; Goyal, Manish; Yenduri, Gowtham; Costa, Antonio; Xu, Xiaoming; O'Connor, Thomas; Burgess, Diane; Chaudhuri, Bodhisattwa (2021). "Artificial neural networks in tandem with molecular descriptors as predictive tools for continuous liposome manufacturing". International Journal of Pharmaceutics. 603 (120713): 120713. doi:10.1016/j.ijpharm.2021.120713. PMID 34019974. S2CID 235093636.

External links[edit]

Wikimedia Commons has media related to Liposomes.
Retrieved from "https://en.wikipedia.org/w/index.php?title=Liposome&oldid=1224737422"